Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy

ConclusionShort-term NET frequently and preferentially upregulates HER2 over other HER family RTKs in early-stage HR+/HER2- BC and may be a promising strategy to identify tumors that utilize HER2 as an early endocrine escape pathway.Clinical trial registryTrial registration number: NCT03219476.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research